M Bate Kenneth (Director) plans to sell 16,575 MDGL shares, about $8M
- Form
- 144
- Filed
- Importance
- Routine
- Accession
- 0001950047-25-008473
- Approximate sale date: Nov 5, 2025
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
- Shares acquired by: Exercise of options under a registered plan
All of M Bate Kenneth's insider filings, holdings and planned sales
Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):
- Sold 1,763 shares at $480.24 on Nov 5, 2025 · Form 4
- Sold 3,259 shares at $481.13 on Nov 5, 2025 · Form 4
- Sold 1,284 shares at $482.41 on Nov 5, 2025 · Form 4
- Sold 2,069 shares at $483.41 on Nov 5, 2025 · Form 4
- Sold 1,931 shares at $484.78 on Nov 5, 2025 · Form 4
- Sold 1,008 shares at $485.54 on Nov 5, 2025 · Form 4
- Sold 827 shares at $486.73 on Nov 5, 2025 · Form 4
- Sold 2,775 shares at $487.49 on Nov 5, 2025 · Form 4
- Sold 696 shares at $489.09 on Nov 5, 2025 · Form 4
- Sold 933 shares at $489.95 on Nov 5, 2025 · Form 4
Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Ionis Pharmaceuticals IONS public float $5.3B, Jun 30, 2025
- Repligen RGEN public float $6.0B, Jun 30, 2025
- Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
- Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
- Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
